FDA Approves First Non-Antipsychotic Drug to Treat Agitation in Alzheimer's Patients

The U.S. Food and Drug Administration has approved a new indication for Auvelity, making it the first non-antipsychotic medication authorized to treat agitation associated with Alzheimer's disease dementia in adults. Originally approved in 2022 for major depressive disorder, this new approval offers clinicians an alternative treatment option that avoids the risks associated with antipsychotic medications. Agitation is a common behavioral symptom in Alzheimer's patients that can significantly impact quality of life for both patients and caregivers. This approval represents an important advancement in managing the neuropsychiatric symptoms of Alzheimer's disease with a different pharmacological approach.